<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02436265</url>
  </required_header>
  <id_info>
    <org_study_id>1408968524</org_study_id>
    <nct_id>NCT02436265</nct_id>
  </id_info>
  <brief_title>Low Dose IV Dexamethasone in Prolonging Caudal Anesthesia in Children Undergoing Genitourinary Surgery</brief_title>
  <official_title>Low Dose IV Dexamethasone in Prolonging Caudal Anesthesia in Children Undergoing Genitourinary Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Caudal injection of local anesthetic is a neuraxial technique routinely performed on young&#xD;
      children for postoperative analgesia after lower abdominal and lower extremity surgical&#xD;
      procedures. One of the major limitations of the use of single shot neuraxial injections for&#xD;
      this purpose is the limited duration of action of the injected local anesthetic. Adjuvant&#xD;
      medications, such as clonidine and epinephrine, have been added to the local anesthetic to&#xD;
      prolong the duration of the neuraxial block, with varying results. Dexamethasone is a&#xD;
      synthetic glucocorticoid steroid commonly used in the perioperative setting for a multitude&#xD;
      of indications, including the prolongation of local anesthetic based analgesia. It has been&#xD;
      shown that the administration of dexamethasone either intravenously or via perineural&#xD;
      injection can significantly increase the duration of analgesia derived from a local&#xD;
      anesthesia based peripheral nerve block. Literature also suggests that the effect of&#xD;
      dexamethasone is equivalent whether given intravenously or perineurally. Interest in&#xD;
      dexamethasone enhanced caudal analgesia exists and a previous study noted that caudal&#xD;
      anesthesia can be prolonged by intravenous dexamethasone. The study was criticized for using&#xD;
      a higher dose of dexamethasone (0.5 mg/kg) than is routinely used in the pediatric population&#xD;
      outside of airway procedures, which may expose patients to dose related side effects of&#xD;
      dexamethasone. A large meta-analysis has suggested that 0.1 mg/kg is effective for analgesic&#xD;
      prolongation, but no direct study of low dose intravenous dexamethasone in combination with&#xD;
      caudal anesthesia has been performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As dexamethasone is an inexpensive and commonly used medication, it would be beneficial to&#xD;
      know if a similar prolongation of analgesia occurs when a local anesthetic is given&#xD;
      neuraxially in combination with low dose intravenous dexamethasone. This project will&#xD;
      investigate the efficacy of low dose intravenous (IV) dexamethasone in prolonging the&#xD;
      duration of post operative analgesia provided by an intraoperative caudal injection of local&#xD;
      anesthetic. All patients will be enrolled in the study the day of surgery, in the&#xD;
      preoperative waiting area. The study will be explained by an anesthesiologist with extensive&#xD;
      knowledge of the protocol. Computer randomization will occur for each patient. Randomization&#xD;
      will not increase the risk to either group as all medications and techniques utilized for&#xD;
      this study are commonly accepted for routine care for these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment/lack of potential subjects fitting criteria&#xD;
  </why_stopped>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 23, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Pain Scores Over 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Will track the trend of pain scores for both arms to note differences in pain score based on intervention received. Pain scores will be based on a patient verbal response of 0-10 pain, 0 being no pain and 10 being worst pain, or with a FLACC score (Face, Legs, Activity, Cry, Consolability scale) of 0-10 if patient unable to communicate verbally</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Group 1 Ropivacaine</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Group 1 Ropivacaine Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Ropivacaine and Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 Ropivacaine/dexamethasone Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine and 0.1mg/kg of intravenous dexamethasone immediately after caudal placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>IV dexamethasone</description>
    <arm_group_label>Group 2 Ropivacaine and Dexamethasone</arm_group_label>
    <other_name>IV Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Ropivacaine only</description>
    <arm_group_label>Group 1 Ropivacaine</arm_group_label>
    <arm_group_label>Group 2 Ropivacaine and Dexamethasone</arm_group_label>
    <other_name>Ropi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 2 to 10 years&#xD;
&#xD;
          -  Scheduled for elective inpatient genitourinary surgical procedure&#xD;
&#xD;
          -  Caudal anesthesia standard of care for surgical procedure&#xD;
&#xD;
          -  have provided parental consent and assent in accordance with the institutional review&#xD;
             board requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal/difficult anatomy&#xD;
&#xD;
          -  known allergy to ropivacaine or dexamethasone&#xD;
&#xD;
          -  history of documented chronic pain&#xD;
&#xD;
          -  existing infection at site of intended injection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aali M Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Desmet M, Braems H, Reynvoet M, Plasschaert S, Van Cauwelaert J, Pottel H, Carlier S, Missant C, Van de Velde M. I.V. and perineural dexamethasone are equivalent in increasing the analgesic duration of a single-shot interscalene block with ropivacaine for shoulder surgery: a prospective, randomized, placebo-controlled study. Br J Anaesth. 2013 Sep;111(3):445-52. doi: 10.1093/bja/aet109. Epub 2013 Apr 15.</citation>
    <PMID>23587875</PMID>
  </reference>
  <reference>
    <citation>Hong JY, Han SW, Kim WO, Kim EJ, Kil HK. Effect of dexamethasone in combination with caudal analgesia on postoperative pain control in day-case paediatric orchiopexy. Br J Anaesth. 2010 Oct;105(4):506-10. doi: 10.1093/bja/aeq187. Epub 2010 Jul 20.</citation>
    <PMID>20659915</PMID>
  </reference>
  <reference>
    <citation>De Oliveira GS Jr, Almeida MD, Benzon HT, McCarthy RJ. Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology. 2011 Sep;115(3):575-88. doi: 10.1097/ALN.0b013e31822a24c2. Review.</citation>
    <PMID>21799397</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2015</study_first_posted>
  <results_first_submitted>May 23, 2019</results_first_submitted>
  <results_first_submitted_qc>April 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2021</results_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Aali M. Shah</investigator_full_name>
    <investigator_title>Aali Shah, MD</investigator_title>
  </responsible_party>
  <keyword>Neuraxial</keyword>
  <keyword>Caudal</keyword>
  <keyword>Block</keyword>
  <keyword>Anesthesia</keyword>
  <keyword>Dexamethasone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 13, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02436265/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 Ropivacaine</title>
          <description>Group 1 Ropivacaine Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine&#xD;
Ropivacaine: Ropivacaine only</description>
        </group>
        <group group_id="P2">
          <title>Group 2 Ropivacaine and Dexamethasone</title>
          <description>Group 2 Ropivacaine/dexamethasone Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine and 0.1mg/kg of intravenous dexamethasone immediately after caudal placement&#xD;
Dexamethasone: IV dexamethasone&#xD;
Ropivacaine: Ropivacaine only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ropivacaine Only Group</title>
          <description>Patients receiving caudals with local anesthetic, but no IV dexamethasone</description>
        </group>
        <group group_id="B2">
          <title>Ropivaciane + IV Dexamethasone</title>
          <description>Patients receiving caudals with local anesthetic +0/1mg/kg IV dexamethasone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Pain Scores Over 24 Hours</title>
        <description>Will track the trend of pain scores for both arms to note differences in pain score based on intervention received. Pain scores will be based on a patient verbal response of 0-10 pain, 0 being no pain and 10 being worst pain, or with a FLACC score (Face, Legs, Activity, Cry, Consolability scale) of 0-10 if patient unable to communicate verbally</description>
        <time_frame>24 hours</time_frame>
        <population>The study was abandoned/terminated. Enrollment in the trial did not reach the target number of subjects needed to achieve target power and was insufficient to produce statistically reliable results. No participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine Only</title>
            <description>caudal analgesia with 0.2% ropivacaine only</description>
          </group>
          <group group_id="O2">
            <title>Ropivaciane + IV Dexamethasone</title>
            <description>Caudal analgesia with IV dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Scores Over 24 Hours</title>
          <description>Will track the trend of pain scores for both arms to note differences in pain score based on intervention received. Pain scores will be based on a patient verbal response of 0-10 pain, 0 being no pain and 10 being worst pain, or with a FLACC score (Face, Legs, Activity, Cry, Consolability scale) of 0-10 if patient unable to communicate verbally</description>
          <population>The study was abandoned/terminated. Enrollment in the trial did not reach the target number of subjects needed to achieve target power and was insufficient to produce statistically reliable results. No participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ropivacaine Only</title>
          <description>Caudal analgesia with 0.2% ropivacaine only</description>
        </group>
        <group group_id="E2">
          <title>Ropivacaine + IV Dexamethasone</title>
          <description>Caudal analgesia with 0.2% ropivacaine only plus IV dexamethasone 0.1 mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was abandoned/terminated. Enrollment in the trial did not reach the target number of subjects needed to achieve target power and was insufficient to produce statistically reliable results. No participants were analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Aali shah MD</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-944-9981</phone>
      <email>ashah9@iuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

